Tyra Biosciences, Inc.TYRANASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank43
5Y CAGR-28.5%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-28.5%/yr
Long-term compound
Percentile
P43
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 10.67% |
| Q3 2025 | 4.77% |
| Q2 2025 | -2.62% |
| Q1 2025 | 12.55% |
| Q4 2024 | -2.28% |
| Q3 2024 | 27.00% |
| Q2 2024 | 4.63% |
| Q1 2024 | -17.39% |
| Q4 2023 | 7.30% |
| Q3 2023 | 58.45% |
| Q2 2023 | 16.85% |
| Q1 2023 | 0.08% |
| Q4 2022 | -4.72% |
| Q3 2022 | -9.40% |
| Q2 2022 | 24.90% |
| Q1 2022 | 33.03% |
| Q4 2021 | 32.20% |
| Q3 2021 | 25.18% |
| Q2 2021 | 24.39% |
| Q1 2021 | 20.29% |
| Q4 2020 | 57.25% |
| Q3 2020 | 31.13% |
| Q2 2020 | 43.00% |
| Q1 2020 | 0.00% |